Nanotop (Human Serum Albumin)

Human Serum Albumin, the active ingredient in Nanotop, is a plasma protein preparation presented as a solution for subcutaneous use. It is used to restore plasma volume and maintain oncotic pressure in patients with hypoalbuminemia or acute fluid loss.

GNH USA supplies Nanotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Nanotop contains human serum albumin and is employed in clinical situations that require plasma volume support or correction of low albumin levels. - Hypoalbuminemia: restores oncotic pressure and improves fluid balance. - Acute burns or trauma: provides volume expansion when large fluid shifts occur. - Major surgery: supports intravascular volume during peri‑operative management. - Liver disease with ascites: helps maintain plasma oncotic pressure and reduces edema.

Human serum albumin may be associated with a range of adverse reactions.

Common Side Effects: - Fever or chills - Local injection site reactions (pain, erythema) - Headache - Nausea or vomiting - Hypotension - Transient rash

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Volume overload leading to pulmonary edema - Thromboembolic events - Hemolysis - Transmission of infectious agents (theoretical risk) - Severe electrolyte disturbances

When using Nanotop, clinicians should observe several safety measures. - Assess baseline albumin levels: determine need for replacement. - Monitor fluid status: avoid overload in patients with cardiac or renal impairment. - Use cautiously in heart failure: risk of volume overload. - Avoid in known hypersensitivity to human serum albumin. - Employ aseptic technique during subcutaneous administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Human serum albumin can interact with other agents affecting fluid balance or protein binding.

Major Interactions (Avoid): - Concurrent use with other colloid volume expanders may cause excessive plasma volume. - Simultaneous administration with high‑dose diuretics can precipitate severe hypovolemia.

Moderate Interactions (Monitor Closely): - Co‑administration with vasopressors may alter hemodynamic response. - Drugs highly bound to albumin (e.g., warfarin, phenytoin) may have altered free concentrations. - Nephrotoxic agents combined with volume expansion require renal function monitoring.